Products and Services
Features & Benefits
Active Extraction Benefits
- Dissociates cfDNA from histones, proteins, and extracellular debris
- 70% higher yields than traditional kits
- Lower plasma volume required for downstream assays
Higher cfDNA Yields
Figure 1. cfDNA was extracted from EDTA plasma from 10 donors using truXTRAC cfDNA and a competing column-based purification kit. Yields were determined by Qubit and the box plot displays yields across ten donors. “X” indicates mean values.
Active Extraction Benefits
- Extract higher complexity cfDNA to unlock the true biology of the sample
- No change in profile between plasma and extracted cfDNA
- ALU247/ALU115 ratio reflects increased complexity of extracted cfDNA
Higher DNA Integrity Index
Figure 2. DNA integrity index as determined by qPCR (Alu247/Alu115 amplification ratios) from cfDNA isolated from EDTA Plasma using truXTRAC cfDNA kit compared to a traditional column-based kit.
Circulating cell-free DNA (cfDNA) are important biomarkers for non-invasive prenatal testing (NIPT), diagnosis, prognosis, and treatment monitoring of cancer, as well as diagnosis of allograft and transplant rejection.
The current methods used for the extraction and purification of cfDNA from whole blood are designed for use with fresh plasma from K3-EDTA-stabilized whole blood, requiring rapid on-site processing; leukocyte lysis and genomic DNA contamination begins shortly after collection. Alternative methods for blood collection such as the Streck Cell-Free DNA™ BCT tubes have been specially designed for cfDNA stabilization, however, they contain fixative-releasing stabilizers that introduce complexities for the extraction step. This introduces biases in the cfDNA population when using passive extraction methodologies. Furthermore, current extraction methods involved complex workflows and were not designed for high-throughput applications.
Collectively, these barriers limit the number of samples that can practically be studied for the discovery and validation of clinically relevant mutations. The Covaris Adaptive Focused Acoustics® (AFA®) enabled truXTRAC cfDNA from Plasma kit is an active method of dissociating and extracting cfDNA from histones and other proteins, as well as apoptotic body-associated cfDNA linked complexes which occur in stabilized plasma.
Active extraction of cfDNA not only significantly increases the yield but also the complexity of the extracted cfDNA. AFA-enabled extraction ensures that the cfDNA profile in the original plasma sample is reflected in the extracted and purified sample. In addition, truXTRAC cfDNA offers a simple and efficient workflow, thereby enabling short turnaround time sample processing and high throughput implementation.
|Part #||Product Name||Description|
|520221||truXTRAC cfDNA Kit – Magnetic Bead (24)||The truXTRAC cfDNA kit contains AFA-optimized reagents and consumables required for extraction and purification of cfDNA from EDTA or Streck plasma with magnetic bead purification.|
Semi-Automated Extraction on the KingFisher Duo Prime:
Covaris provides tools and technologies to improve pre-analytical sample preparation, enable novel drug formulations, and manage compounds in the drug discovery process.